Theravance Biopharma Inc Cash Flow-to-Debt Ratio
Theravance Biopharma Inc cash flow-to-debt ratio. Theravance Biopharma Inc (TBPH) has a Cash Flow-to-Debt Ratio of -0.03x as of December 2025, meaning its operating cash flow of $-6.06 Million could theoretically repay 0% of its total liabilities ($188.85 Million) in one year. Check cash flow quality index of Theravance Biopharma Inc to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Theravance Biopharma Inc (2011–2025)
Cash flow-to-debt ratio of Theravance Biopharma Inc from 2011 to 2025. Historical debt coverage capacity for Theravance Biopharma Inc across 15 annual periods. Check total reinvestment intensity of Theravance Biopharma Inc to assess the company's total reinvestment commitment from operating cash flow.
Theravance Biopharma Inc Cash Flow-to-Debt Ratio by Year (2011–2025)
Theravance Biopharma Inc cash flow-to-debt ratio by year from 2011 to 2025. Year-by-year debt coverage analysis for Theravance Biopharma Inc. For the full cash flow conversion analysis, see Theravance Biopharma Inc (TBPH) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 1.26x | $238.54 Million | $188.85 Million | ▲ +2055.9% |
| 2024 | -0.06x | $-11.54 Million | $178.62 Million | ▲ +59.6% |
| 2023 | -0.16x | $-27.00 Million | $169.00 Million | ▲ +85.9% |
| 2022 | -1.13x | $-186.99 Million | $165.60 Million | ▼ -287.5% |
| 2021 | -0.29x | $-207.86 Million | $713.39 Million | ▲ +10.1% |
| 2020 | -0.32x | $-250.40 Million | $772.81 Million | ▲ +13.9% |
| 2019 | -0.38x | $-238.20 Million | $632.67 Million | ▼ -104.1% |
| 2018 | -0.18x | $-112.87 Million | $611.82 Million | ▲ +70.1% |
| 2017 | -0.62x | $-201.05 Million | $326.22 Million | ▼ -79.9% |
| 2016 | -0.34x | $-98.99 Million | $289.02 Million | ▲ +88.4% |
| 2015 | -2.96x | $-168.86 Million | $57.05 Million | ▲ +18.9% |
| 2014 | -3.65x | $-175.16 Million | $47.98 Million | ▼ -27.4% |
| 2013 | -2.87x | $-120.96 Million | $42.21 Million | ▲ +45.5% |
| 2012 | -5.25x | $-119.11 Million | $22.67 Million | ▼ -873.2% |
| 2011 | -0.54x | $-83.43 Million | $154.54 Million | — |